Synonyms: MORAb-022
Compound class:
Antibody
Comment: Gimsilumab (MORAb-022) is an investigational, fully human IgG1 monoclonal antibody being evaluated for its potential in the treatment of multiple inflammatory diseases and cancer. It targets granulocyte-macrophage colony stimulating factor (GM-CSF, CSF2), a growth factor involved in autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and asthma. In the cancer setting, MORAb-022-mediated blocking of CSF2 produces a pro-immunity microenvironment that leads to tumour tissue death in preclinical studies. Peptide sequences (from the WHO INN submission for gimsilumab) match sequences 8 and 12 from Morphotek Inc. patent WO2007092939 [1], and these sequences belong to monoclonal antibody clone G9 specified in the patent.
|
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
10534 | gimsilumab |
Synonyms |
MORAb-022 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 756 |
Other databases | |
GtoPdb PubChem SID | 340590254 |
Search PubMed clinical trials | gimsilumab |
Search PubMed titles | gimsilumab |
Search PubMed titles/abstracts | gimsilumab |